证券代码：300086 证券简称：康芝药业 公告编号：2026-004 康芝药业股份有限公司 关于公司产品中选河北省牵头京津冀赣化学药品集中带量采购的 公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"）于近期参加河北省牵头京津冀 赣化学药品集中带量采购(文件编号 HBYPJC-2025-05) 申报工作，公司产品盐酸左 西替利嗪颗粒中选本次集中带量采购。现将相关情况公告如下： | 中选产 品 | | 批件号 | | 规格 | 适应症 | 包装 数量 | 中选价格 （单位： | 首年约定采购量（袋） | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 元/盒） | 河北 江西 | | | 盐 酸 | 左 | 国 药 字 | 准 | 2.5mg | 荨麻疹、过敏性鼻 | 12 袋 | 36.24 | 729,299 | 1,006,393 | | 西 替 利 | | H20150042 | | | 炎、湿疹、皮炎、 ...

Core Viewpoint - The company, Kangzhi Pharmaceutical (300086.SZ), has stated that it currently has no projects in collaboration with brain-computer interface companies [1] Group 1 - The company confirmed its lack of partnerships with brain-computer interface firms as of now [1]

Group 1 - The core point of the article is that Kangzhi Pharmaceutical announced the pledge extension of shares held by its controlling shareholder, Hainan Hongshi Investment Co., Ltd. [1] - The total number of shares pledged in this extension amounts to 84,900,000 shares [1]

Group 1 - Company announced that its controlling shareholder, Hainan Hongshi Investment Co., Ltd., has notified the company about the extension of the pledge on part of its shares [1] - As of the announcement date, the total number of pledged shares by Hongshi Investment is 95.9 million shares, which accounts for 94.69% of its total holdings [1]

证券代码：300086 证券简称：康芝药业 公告编号：2026-003 康芝药业股份有限公司 关于公司控股股东部分股份质押展期的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"或"康芝药业"）于近日接到公司 控股股东海南宏氏投资有限公司（以下简称"宏氏投资"）的通知，获悉其将所持 有公司的部分股份办理了质押展期，现将有关情况说明如下： 一、控股股东股份质押展期基本情况 1 股东 名称 是否为控 股股东及 其一致行 动人 本次质押数 量（股） 占其所 持股份 比例 占公司总 股本比例 是否 为限 售股 是否为 补充质 押 质押 起始 日 原质押 到期日 展期后 质押到 期日 质权人 质押用 途 宏氏 投资 控股股东 9,560,000 9.44% 2.10% 否 否 2023. 1.30 2026.1. 19 2027.7. 15 海 口 市 农 村 信 用 合 作 联 社 本次质 押展期， 不涉及 新增融 资，原融 资继续 用于补 充经营 所需资 金 570,000 0.56% 0.13% 否 否 2023. 1.30 五 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

Core Viewpoint - Kangzhi Pharmaceutical announced the approval of a proposal to adjust its organizational structure during the second meeting of the seventh board of directors [2] Group 1 - The company held its second meeting of the seventh board of directors on January 15 [2] - The board approved the proposal regarding the adjustment of the company's organizational structure [2]

Group 1 - The core point of the article is the appointment of Mr. Wang Yong as a senior management personnel by the board of directors of Kangzhi Pharmaceutical (300086) [1]

Group 1 - The company announced the appointment of Wang Yong as the Vice President, effective from the date of the board meeting approval until the end of the current board's term [1]

Group 1 - The company Kangzhi Pharmaceutical announced that its seventh second board meeting will be held on January 15, 2026, in Haikou, focusing on organizational structure adjustments [1] - The meeting will be conducted both in-person and via remote voting [1] Group 2 - A report indicates that a "budget version" of the Tesla Model 3 may enter the Chinese market, priced under 200,000 yuan, with a range of 480 kilometers [1] - Significant adjustments are also noted in the U.S. market regarding autonomous driving [1]